Navigation Links
Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
Date:1/30/2009

Stemedica Cell Technologies, Inc., a leader in adult stem cell production, announced today the appointment of Michael Bayer, MD, as Director, Medical Services. Dr. Bayer will be responsible for developing pre-clinical and clinical trial protocols for use by research centers conducting pre-clinical and clinical trials using Stemedica products.

San Diego, CA (PRWEB) January 30, 2009 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell production, announced today the appointment of Michael Bayer, MD, as Director, Medical Services. Dr. Bayer will be responsible for developing pre-clinical and clinical trial protocols for use by research centers conducting pre-clinical and clinical trials using Stemedica products.

An Orthopedic Surgeon and Clinician, Dr. Bayer's specialty is Translational Medicine - taking laboratory research and results and applying them in new patient treatments.    World renowned for inventing an arthroscopic surgical technique for repairing rotator cuff injuries, Dr. Bayer has worked with major clinical research institutions and physicians around the world to bring new technology safely and successfully into the medical marketplace.

Dr. Bayer's new role at Stemedica was warmly welcomed by Dr. Nikolai Tankovich, President, Chief Medical Officer of Stemedica. "I am very impressed with Dr. Bayer's long track record of translating laboratory results to practical surgery and treatments. Dr. Bayer is a brilliant surgeon and clinician and we feel very fortunate to have attracted his interest and to have brought about this significant appointment. I am looking forward to working with him to advance our work," said Dr. Tankovich.

For the past year, Dr. Bayer has been involved in a Fellowship Study Program with Dr. Nikolay Mironov, the world's foremost adult stem cell clinician, and with Dr. Alex Kharazi, Stemedica's Vice President - R&D and Manufacturing.

"My interest in Stemedica and their technology quickly deepened when I became aware of the difference that treatments were having on the quality of life for patients participating in clinical trials. After a year of study and interaction with Drs. Mironov and Kharazi, I believe I have as strong a knowledge of stem cell effects in research and medical applications. I was so inspired by what I had learned and witnessed first hand from clinical outcomes of patients participating in overseas clinical studies that I asked Stemedica if there was any way I could support the company with my translational knowledge and experience. In my new role, I know I will be making a difference in a very important and evolving area of medicine. That really matters to me," said Dr. Michael Bayer.

"We realized from the first day we met Dr. Bayer that he had the experience in medical technology innovation and in translational medicine that would be valuable to a company like ours. After his fellowship with Drs. Mironov and Kharazi we knew he had the commitment and first hand knowledge to support the ongoing development of our pre-clinical and clinical trials treatment protocols. We created the role for Dr. Bayer based on his interest in working with us and his desire to impact the quality of life possibilities for no-option patients. Stemedica is delighted to have Dr. Bayer join our team," said Maynard Howe, CEO and Vice Chairman at Stemedica.

In addition to his professional work, Dr. Bayer co-founded "The Free Wheelchair Mission", a non-profit that has delivered wheel chairs to over 370,000 people in some of the poorest countries worldwide. (www.freewheelchairmission.org)

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (http://www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is headquartered in San Diego, California.

From more information regarding Stemedica Cell Technologies or the Dr. Michael Bayer appointment, contact Dave McGuigan at dmcguigan (at) stemedica (dot) com.

# # #

Read the full story at http://www.prweb.com/releases/stemedica/adult-stem-cell-research/prweb1936934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Nektar Announces Retirement of Irwin Lerner from Board of Directors
2. Cardica Announces Fiscal 2009 Second Quarter Financial Results
3. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
4. Omnitura Therapeutics Announces Private Placement Financing
5. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
6. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
7. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
8. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
9. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
(Date:2/22/2017)... Dublin - Research and Markets has announced ... Type, By Application, By End User, By Region, By Country: Opportunities ... ... is forecasted to grow at a CAGR of 11.33% during 2016-2021. ... protection market is driven by the surging demand for less toxic ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, ... , Perkins joins Pennside after more than a decade with leading market research ...
(Date:2/21/2017)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... months ended December 31, 2016. SQI is ... company that develops and commercializes proprietary technologies and products for ... ... milestones achieved in fiscal 2016," said Andrew Morris , ...
(Date:2/21/2017)... San Francisco, CA (PRWEB) , ... February 21, ... ... is pleased to announce that Dr. Trevor Heritage has joined its executive team ... a revolutionary system designed to provide insights to help improve the diagnosis and ...
Breaking Biology Technology:
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements of ... (IAM) lifecycle is comprised of a comprehensive set ... purpose of maintaining digital identities and providing a ... applications. There are significant number of programs opted ... to time by optimizing processes and changing policies. ...
(Date:1/19/2017)... 19, 2017 According to a new report published by ... - 2022," the global biometric sensor market is expected to garner $1.5 billion ... 2015, Asia-Pacific dominated the global market and contributed over ... Continue Reading ... ...
Breaking Biology News(10 mins):